Elevance Health Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Gail Boudreaux
Chief executive officer
US$20.5m
Total compensation
| CEO salary percentage | 7.82% |
| CEO tenure | 8yrs |
| CEO ownership | 0.06% |
| Management average tenure | 7.8yrs |
| Board average tenure | 12.3yrs |
Recent management updates
Recent updates
Elevance: Checking Out The Q3 Report
Oct 22Positive Sentiment Still Eludes Elevance Health, Inc. (NYSE:ELV) Following 25% Share Price Slump
Jul 29
Not Many Are Piling Into Elevance Health, Inc. (NYSE:ELV) Just Yet
May 31Elevance Health (NYSE:ELV) Has A Pretty Healthy Balance Sheet
May 11Elevance Health: Carelon Growth Not Fully Appreciated
Apr 23Elevance Health (NYSE:ELV) Has More To Do To Multiply In Value Going Forward
Apr 15Elevance Health: A Hidden Gem Amongst Healthcare Turbulence
Apr 15Elevance Health: Add A Little Bit Of Health To Your Defensive Portfolio
Mar 13Maximizing Returns: 3 Compelling Reasons To Invest In Elevance Health Now
Feb 27Elevance Health (NYSE:ELV) Is Increasing Its Dividend To $1.71
Feb 18It's A Story Of Risk Vs Reward With Elevance Health, Inc. (NYSE:ELV)
Feb 10Elevance Health: Trading At Depressed Levels, So We Added Modestly
Jan 30Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.71
Jan 26Elevance Health Q4 2024 Earnings: Managed Care Continues To Impress
Jan 23Is There Now An Opportunity In Elevance Health, Inc. (NYSE:ELV)?
Jan 15ELV Market Outlook
This industry includes companies primarily engaged in providing health insurance products, managed care plans, and related healthcare services. These companies play a critical role in financing and maElevance Health Is An Undervalued Healthcare Juggernaut
Dec 26Returns Are Gaining Momentum At Elevance Health (NYSE:ELV)
Dec 15Elevance Health: A Quality Underpriced Stock Returning To Health
Dec 11Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 30Elevance Health: A Bad Q3 Was Almost Inevitable Given Industry Headwinds
Oct 17Elevance: Our Top Value Pick Trading At 12.5x Earnings And Growing At 12.5%
Oct 10Elevance Health: Strong Earnings Growth Supports Strong Dividend Growth
Sep 06Elevance Health: Healthcare Services Segment Is Gaining Traction
Jul 31Elevance Health: Buy A Dividend Growth Machine
Jul 18Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Jun 28Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$6b |
| Jun 30 2025 | n/a | n/a | US$5b |
| Mar 31 2025 | n/a | n/a | US$6b |
| Dec 31 2024 | US$20m | US$2m | US$6b |
| Sep 30 2024 | n/a | n/a | US$6b |
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
Compensation vs Market: Gail's total compensation ($USD20.47M) is above average for companies of similar size in the US market ($USD13.47M).
Compensation vs Earnings: Gail's compensation has been consistent with company performance over the past year.
CEO
Gail Boudreaux (64 yo)
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8yrs | US$20.47m | 0.059% $ 41.9m | |
| Executive VP & CFO | 2yrs | US$6.87m | 0.0018% $ 1.2m | |
| Executive VP and President of Carelon & CarelonRx | 11.4yrs | US$6.35m | 0.0093% $ 6.5m | |
| Executive VP & President of Commercial Health Benefits | no data | US$5.79m | 0.0023% $ 1.6m | |
| Executive VP & President of Government Health Benefits | 7.4yrs | US$6.29m | 0.012% $ 8.4m | |
| SVP, Treasurer & Chief Investment Officer | 7.6yrs | no data | no data | |
| Senior VP | 10yrs | no data | 0.00060% $ 423.0k | |
| Vice President of Investor Relations | no data | no data | no data | |
| EVP & Chief Legal Officer | no data | no data | 0.00083% $ 585.1k | |
| Senior Vice President of Public Affairs | 12yrs | no data | no data | |
| Chief Strategy Officer & Interim Chief Marketing Officer | 1.7yrs | no data | no data | |
| EVP & Chief HR Officer | no data | no data | 0.00047% $ 331.3k |
Experienced Management: ELV's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8yrs | US$20.47m | 0.059% $ 41.9m | |
| Independent Chair | 21yrs | US$392.61k | 0.0031% $ 2.2m | |
| Independent Director | 12.3yrs | US$345.00k | no data | |
| Independent Director | 7.8yrs | US$392.61k | 0.00034% $ 239.7k | |
| Independent Director | 11.5yrs | US$375.00k | no data | |
| Independent Director | 6.1yrs | US$376.37k | 0.0016% $ 1.1m | |
| Independent Director | 14.3yrs | US$352.61k | 0.0033% $ 2.3m | |
| Member of Advisory Board | 12.3yrs | no data | no data | |
| Member of Advisory Board | 12.3yrs | no data | no data | |
| Member of Advisory Board | 12.3yrs | no data | no data | |
| Member of Advisory Board | 12.3yrs | no data | no data | |
| Member of Advisory Board | 12.3yrs | no data | no data |
Experienced Board: ELV's board of directors are seasoned and experienced ( 12.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 10:17 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elevance Health, Inc. is covered by 40 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Hua Ha | Baird |
| Joshua Raskin | Barclays |